{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:58Z","timestamp":1792036858717,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024NSFSC1292"],"award-info":[{"award-number":["2024NSFSC1292"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021YJ0145"],"award-info":[{"award-number":["2021YJ0145"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the general program of General Hospital of Western Theater Command","award":["2021-XZYG-B32"],"award-info":[{"award-number":["2021-XZYG-B32"]}]},{"name":"the incubation program of General Hospital of Western Theater command","award":["2021-XZYG-C45"],"award-info":[{"award-number":["2021-XZYG-C45"]}]},{"name":"the incubation program of General Hospital of Western Theater command","award":["2021-XZYG-C46"],"award-info":[{"award-number":["2021-XZYG-C46"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01713-2","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T01:01:24Z","timestamp":1747616484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Hao","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-hui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-qiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-han","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-tao","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-li","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-yi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"1","key":"1713_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel[J]. J Hematol Oncol. 2024;17(1):42.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1713_CR2","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/ajh.27469","volume":"99","author":"Y Qi","year":"2024","unstructured":"Qi Y, Li H, Qi K, et al. Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy[J]. Am J Hematol. 2024;99(12):2286\u201395.","journal-title":"Am J Hematol"},{"key":"1713_CR3","doi-asserted-by":"publisher","first-page":"720571","DOI":"10.3389\/fimmu.2021.720571","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng H, Liu M, Yuan T, et al. Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease[J]. Front Immunol. 2021;12:720571.","journal-title":"Front Immunol"},{"issue":"9","key":"1713_CR4","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","volume":"34","author":"N Gagelmann","year":"2020","unstructured":"Gagelmann N, Riecken K, Wolschke C, et al. Development of CAR-T cell therapies for multiple myeloma[J]. Leukemia. 2020;34(9):2317\u201332.","journal-title":"Leukemia"},{"issue":"6","key":"1713_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","volume":"29","author":"KR Reyes","year":"2023","unstructured":"Reyes KR, Huang CY, Lo M, et al. Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma[J]. Transplant Cell Ther. 2023;29(6):350\u20135.","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"1713_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3892\/etm.2023.12170","volume":"26","author":"X Zhang","year":"2023","unstructured":"Zhang X, Ouyang C, Sun G, et al. Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma[J]. Exp Ther Med. 2023;26(4):471.","journal-title":"Exp Ther Med"},{"issue":"1","key":"1713_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma[J]. J Hematol Oncol. 2021;14(1):161.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1713_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"38","author":"C Li","year":"2024","unstructured":"Li C, Xu J, Luo W, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma[J]. Leukemia. 2024;38(1):149\u201359.","journal-title":"Leukemia"},{"issue":"14","key":"1713_CR9","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, Li H, Yan Z, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial[J]. J Clin Oncol. 2023;41(14):2583\u201393.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1713_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma[J]. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"10","key":"1713_CR11","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","volume":"11","author":"D Zhou","year":"2024","unstructured":"Zhou D, Sun Q, Xia J, et al. Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial[J]. Lancet Haematol. 2024;11(10):e751\u201360.","journal-title":"Lancet Haematol"},{"issue":"2","key":"1713_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"DLC Fernandez","year":"2020","unstructured":"Fernandez DLC, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma[J]. Blood Cancer Discov. 2020;1(2):146\u201354.","journal-title":"Blood Cancer Discov"}],"updated-by":[{"DOI":"10.1186\/s13045-025-01714-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000}}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01713-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01713-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01713-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T06:01:38Z","timestamp":1749016898000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01713-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01713-2","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13045-025-01714-1","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13045-025-01714-1","URL":"https:\/\/doi.org\/10.1186\/s13045-025-01714-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of People's Liberation Army The General Hospital of Western Theater Command (Approval Number: 2024EC1-ky033). All experiments were conducted in compliance with relevant ethical guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Declaration of interests AHC is a founding member of Shanghai YaKe Biotechnology, a biotechnology company focusing on research and development of tumour cellular immunotherapy. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}